undamentalytics Newsletter
Sign in

Vir Biotechnology, Inc. income statement

In fiscal 2025, Vir Biotechnology, Inc. reported revenue of $68.6m, down 7.6% on the year before, operating income of −$479m (a -699.2% margin) and net income of −$438m, or −$3.16 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3118761,0951,616867469303
Cost of revenue——0066146310—
Gross profit——8761,0301,469837369—
Research and development63100148302448475580506456484
Selling, general and administrative——38711611621741199299
General and administrative2229————————
Operating income−81−119−178−297421833−684−587−479−280
Income before tax−81−116−175−299550754−628−523−438−251
Income tax−11−00021238−13−100
Net income−70−116−175−299529516−615−522−438−252
Diluted EPS−$2.03−$0.94−$1.44−$2.51$3.96$3.83−$4.59−$3.83−$3.16−$1.69
Diluted shares (average)34m123m121m119m133m135m134m136m139m149m
EBITDA−81−117−175−293426840−665−573−468−269

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: VCEL vs VIRADPT vs VIRARVN vs VIRSNDX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vir Biotechnology, Inc.